Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JASMINE study of ABP 798 versus rituximab in CD20-positive B-cell non-Hodgkin lymphoma
MOH_2017-09-18_000322Phase 3Active, not recruiting
- Sponsor
- Amgen
- Start
- Jun 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial of rituximab in non-Hodgkin lymphoma (NHL) and follicular lymphoma (FL) (2 arms), sponsored by Amgen. Primary endpoints: overall response rate, peak drug concentration and 3 more. Started Jun 2017; status: active, not recruiting.
02
Drugs
rituximab
03
Conditions
non-Hodgkin lymphoma (NHL)follicular lymphoma (FL)
Beyond the preview
Go deeper on MOH_2017-09-18_000322.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-09-18_000322.